Eli Lilly and Company (NYSE:LLY) had its price objective upped by research analysts at Barclays PLC from $90.00 to $98.00 in a research note issued on Friday. The brokerage currently has an “overweight” rating on the stock. Barclays PLC’s price target points to a potential upside of 13.39% from the stock’s previous close.
Other analysts also recently issued reports about the company. TheStreet raised Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. Citigroup Inc. reaffirmed a “buy” rating and issued a $100.00 target price on shares of Eli Lilly and in a research report on Tuesday, July 4th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $93.00 target price on shares of Eli Lilly and in a research report on Thursday, June 22nd. Berenberg Bank reaffirmed a “buy” rating and issued a $100.00 target price on shares of Eli Lilly and in a research report on Thursday, July 27th. Finally, Deutsche Bank AG reaffirmed a “buy” rating and issued a $91.00 target price (up from $90.00) on shares of Eli Lilly and in a research report on Monday, July 17th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $88.97.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. The firm had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period last year, the company earned $0.86 EPS.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/10/13/eli-lilly-and-company-lly-given-new-98-00-price-target-at-barclays-plc.html.
Hedge funds have recently bought and sold shares of the company. Acrospire Investment Management LLC grew its stake in shares of Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after buying an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC acquired a new stake in shares of Eli Lilly and in the second quarter valued at about $128,000. San Francisco Sentry Investment Group CA acquired a new stake in shares of Eli Lilly and in the second quarter valued at about $129,000. Heritage Trust Co acquired a new stake in shares of Eli Lilly and in the first quarter valued at about $135,000. Finally, Point72 Asia Hong Kong Ltd grew its stake in shares of Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares in the last quarter. Institutional investors and hedge funds own 75.72% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.